Multifunctional Nanomedicine for Precision Theranostics in Hepatic Fibrosis: From Rational Design to Clinical Translation.
- 1Department of Oncological and Vascular Intervention, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
- 2College of Medical Imaging, Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China.
- 3Department of Radiology, Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030032, People's Republic of China.
Abstract
Hepatic fibrosis (HF) is a pathological wound-healing response to chronic liver injury that can progress to cirrhosis and hepatocellular carcinoma. Although resmetirom and semaglutide have been approved for noncirrhotic metabolic dysfunction-associated steatohepatitis with fibrosis, they are restricted to a single etiology, and no nanomedicine has yet achieved clinical approval for HF. The translational bottleneck arises from the multicellular complexity of fibrogenesis, suboptimal pharmacokinetics and off-target toxicity of conventional therapeutics, and formidable biological barriers of the diseased hepatic microenvironment. This review provides an integrated, mechanism-to-translation analysis of multifunctional nanomedicines for precision HF theranostics. The pathophysiological mechanisms governing hepatic stellate cell activation and the fibrotic niche are dissected to delineate actionable targets and delivery barriers. Major nanocarrier classes (lipid-based, polymeric, inorganic, and biologically-derived) are critically evaluated with respect to physicochemical characteristics, targeting efficiency, and suitability for the fibrotic liver. Theranostic strategies spanning passive, active, and microenvironment-responsive targeting are synthesized, with emphasis on multifunctional platforms integrating anti-inflammatory, antifibrotic, gene-based, and immunomodulatory interventions. The clinical translation landscape is critically assessed, and technical, practical, and regulatory barriers are systematically analyzed. By distinguishing established evidence from emerging possibilities and prioritizing translation requirements, this review offers a rational framework for guiding next-generation precision nanomedicines toward clinical viability in HF.
Related
- Artificial Intelligence-Enabled Nanomedicine in Precision Oncology: Diagnosis, Targeted Therapy, and Clinical Translation.
- Carboxymethylcellulose/Hyaluronic Acid Hybrid Nanoconjugates: Toward Multifunctional Platforms for Melanoma Skin Cancer Theranostics.
- Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation.
- A NIR-II AIEgen with superior fluorescence and photothermal performance for precision theranostics
- Artificial intelligence and machine learning-guided bio-orthogonal engineering of smart soft polymeric nanocarriers for precision drug delivery and translational nanomedicine
BibTeX
@article{li2026multifunctional,
title = {{Multifunctional Nanomedicine for Precision Theranostics in Hepatic Fibrosis: From Rational Design to Clinical Translation.}},
author = {Yanan Li and Yanjiao Gong and Xinze Li and Susu Yan and Juan Yu and Zijun Qiu and Shuaibin Yang and Xiangli Yang and Duiping Feng},
journal = {International journal of nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s646535},
url = {https://europepmc.org/article/MED/42974159},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Multifunctional Nanomedicine for Precision Theranostics in Hepatic Fibrosis: From Rational Design to Clinical Translation.
AU - Yanan Li
AU - Yanjiao Gong
AU - Xinze Li
AU - Susu Yan
AU - Juan Yu
AU - Zijun Qiu
AU - Shuaibin Yang
AU - Xiangli Yang
AU - Duiping Feng
PY - 2026
DA - 2026/10/29
JO - International journal of nanomedicine
DO - 10.2147/ijn.s646535
UR - https://europepmc.org/article/MED/42974159
AB - Hepatic fibrosis (HF) is a pathological wound-healing response to chronic liver injury that can progress to cirrhosis and hepatocellular carcinoma. Although resmetirom and semaglutide have been approved for noncirrhotic metabolic dysfunction-associated steatohepatitis with fibrosis, they are restricted to a single etiology, and no nanomedicine has yet achieved clinical approval for HF. The translational bottleneck arises from the multicellular complexity of fibrogenesis, suboptimal pharmacokinetics and off-target toxicity of conventional therapeutics, and formidable biological barriers of the diseased hepatic microenvironment. This review provides an integrated, mechanism-to-translation analysis of multifunctional nanomedicines for precision HF theranostics. The pathophysiological mechanisms governing hepatic stellate cell activation and the fibrotic niche are dissected to delineate actionable targets and delivery barriers. Major nanocarrier classes (lipid-based, polymeric, inorganic, and biologically-derived) are critically evaluated with respect to physicochemical characteristics, targeting efficiency, and suitability for the fibrotic liver. Theranostic strategies spanning passive, active, and microenvironment-responsive targeting are synthesized, with emphasis on multifunctional platforms integrating anti-inflammatory, antifibrotic, gene-based, and immunomodulatory interventions. The clinical translation landscape is critically assessed, and technical, practical, and regulatory barriers are systematically analyzed. By distinguishing established evidence from emerging possibilities and prioritizing translation requirements, this review offers a rational framework for guiding next-generation precision nanomedicines toward clinical viability in HF.
SN - 1176-9114
SN - 1178-2013
ER -